FDA expands Qulipta indication to include chronic migraine prevention

FDA expands Qulipta indication to include chronic migraine prevention

Source: 
Healio
snippet: 

Qulipta, an oral CGRP receptor antagonist, has been approved to prevent chronic and episodic migraine in adults.
FDA approval was based on positive results from the phase 3 PROGRESS trial.